Development of diagnostic biomarkers for detecting diabetic retinopathy at early stages using quantitative proteomics

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Jin, Jonghwa ^a   Min, Hophil ^a   Kim, Sang Jin ^b   Oh, Sohee ^c   Kim, Kyunggon ^a   Yu, Hyeong Gon ^a   Park, Taesung ^d   Kim, Youngsoo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR LIKE PROTEIN 2; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A4; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CD14 ANTIGEN; CLUSTERIN; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C7; CYTOKERATIN 1; FIBRONECTIN; FIBRONECTIN 1; GELSOLIN; HEMOGLOBIN A1C; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H2; KERATIN TYPE II; KERATIN TYPE II CYTOSKELETAL 1; N ACETYLGLUCOSAMINYLTRANSFERASE; N ACETYLLACTOSAMINIDE BETA 1,3 N ACETYLGLUCOSAMINYLTRANSFERASE; PROTEIN; SERPIN F1; UNCLASSIFIED DRUG; VITRONECTIN;

ACTIN FILAMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA MINING; DIABETIC RETINOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE SEVERITY; DOWN REGULATION; ERROR; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIMIT OF QUANTITATION; MALE; MOLECULAR WEIGHT; PEPTIDE SYNTHESIS; PLASMA CHARACTERISTICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STANDARD; VITREOUS BODY; EARLY DIAGNOSIS; MASS SPECTROMETRY; METABOLISM; PROCEDURES;

BIOMARKERS; DATA MINING; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 84948400547     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/6571976     Document Type: Article

References (42)

1. T. A. Ciulla, A. G. Amador, and B. Zinman, "Diabetic retinopa-thy and diabetic macular edema: pathophysiology, screening, and novel therapies," Diabetes Care, vol. 26, no. 9, pp. 2653-2664, 2003.
2. S. J. Glover, P. I. Burgess, D. B. Cohen et al., "Prevalence of diabetic retinopathy, cataract and visual impairment in patients with diabetes in sub-Saharan Africa," British Journal of Ophthalmology, vol. 96, no. 2, pp. 156-161, 2012.
3. V. Sundling, C. G. P. Platou, R. W. Jansson, G. Bertelsen, E. Wøllo, and P. Gulbrandsen, "Retinopathy and visual impairment in diabetes, impaired glucose tolerance and normal glucose tolerance: the Nord-Trøndelag Health Study (the HUNT study)," Acta Ophthalmologica, vol. 90, no. 3, pp. 237-243, 2012.
4. H. Lewis, G. W. Abrams, M. S. Blumenkranz, and R. V. Campo, "Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction," Ophthalmology, vol. 99, no. 5, pp. 753-759, 1992.
5. G. B. Arden, A. M. P. Hamilton, J. Wilson-Holt, S. Ryan, J. S. Yudkin, and A. Kurtz, "Pattern electroretinograms become abnormal when background diabetic retinopathy deteriorates to a preproliferative stage: possible use as a screening test," British Journal of Ophthalmology, vol. 70, no. 5, pp. 330-335, 1986.
6. T. Shitama, H. Hayashi, S. Noge et al., "Proteome profling of vitreoretinal diseases by cluster analysis," Proteomics: Clinical Applications, vol. 2, no. 9, pp. 1265-1280, 2008.
7. S. Rangasamy, P. G. McGuire, and A. Das, "Diabetic retinopa-thy and infammation: novel therapeutic targets," Middle East African Journal of Ophthalmology, vol. 19, no. 1, pp. 52-59, 2012.
8. S. Gutman and L. G. Kessler, "Te US Food and Drug Administration perspective on cancer biomarker development," Nature Reviews Cancer, vol. 6, no. 7, pp. 565-571, 2006.
9. M. Polanski and N. L. Anderson, "A list of candidate cancer biomarkers for targeted proteomics," Biomarker Insights, vol. 1, pp. 1-48, 2007.
10. S. Surinova, R. Schiess, R. Hüttenhain, F. Cerciello, B. Wollscheid, and R. Aebersold, "On the development of plasma protein biomarkers," Journal of Proteome Research, vol. 10, no. 1, pp. 5-16, 2011.
11. S. M. Hewitt, J. Dear, and R. A. Star, "Discovery of protein biomarkers for renal diseases," Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1677-1689, 2004.
12. L. R. Bandara, M. D. Kelley, E. A. Lock, and S. Kennedy, "A potential biomarker of kidney damage identifed by proteomics: preliminary fndings," Biomarkers, vol. 8, no. 4, pp. 272-286, 2003.
13. J. Jin, Y. H. Ku, Y. Kim et al., "Diferential proteome profling using iTRAQ in microalbuminuric and normoalbuminuric type 2 diabetic patients," Experimental Diabetes Research, vol. 2012, Article ID 168602, 31 pages, 2012.
14. N. L. Anderson, M. Polanski, R. Pieper et al., "Te human plasma proteome: a nonredundant list developed by combination of four separate sources," Molecular-Cellular Proteomics, vol. 3, no. 4, pp. 311-326, 2004.
15. 2O metabolic labeling," Molecular & Cellular Proteomics, vol. 11, no. 7, article M111.014209, 2012.
16. L. J. Zimmerman, M. Li, W. G. Yarbrough, R. J. C. Slebos, and D. C. Liebler, "Global stability of plasma proteomes for mass spectrometry-based analyses," Molecular & Cellular Proteomics, vol. 11, no. 6, article M111.014340, 2012.
17. N. Rifai, M. A. Gillette, and S. A. Carr, "Protein biomarker discovery and validation: the long and uncertain path to clinical utility," Nature Biotechnology, vol. 24, no. 8, pp. 971-983, 2006.
18. B.-B. Gao, X. Chen, N. Timothy, L. P. Aiello, and E. P. Feener, "Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy," Journal of Proteome Research, vol. 7, no. 6, pp. 2516-2525, 2008.
19. B.-B. Gao, A. Clermont, S. Rook et al., "Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation," Nature Medicine, vol. 13, no. 2, pp. 181-188, 2007.
20. K. Yamane, A. Minamoto, H. Yamashita et al., "Proteome analysis of human vitreous proteins," Molecular & Cellular Proteomics, vol. 2, no. 11, pp. 1177-1187, 2003.
21. A. Decanini, P. R. Karunadharma, C. L. Nordgaard, X. Feng, T. W. Olsen, and D. A. Ferrington, "Human retinal pigment epithelium proteome changes in early diabetes," Diabetologia, vol. 51, no. 6, pp. 1051-1061, 2008.
22. M. García-Ramírez, F. Canals, C. Hernández et al., "Proteomic analysis of human vitreous fuid by fuorescence-based diference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy," Diabetologia, vol. 50, no. 6, pp. 1294-1303, 2007.
23. T. Kim, J. K. Sang, K. Kim et al., "Profling of vitreous pro-teomes from proliferative diabetic retinopathy and nondiabetic patients," Proteomics, vol. 7, no. 22, pp. 4203-4215, 2007.
24. K. Kim, S. J. Kim, D. Han et al., "Verifcation of multimarkers for detection of early stage diabetic retinopathy using multiple reaction monitoring," Journal of Proteome Research, vol. 12, no. 3, pp. 1078-1089, 2013.
25. H. Wang, L. Feng, J. W. Hu, C. L. Xie, and F. Wang, "Characterisation of the vitreous proteome in proliferative diabetic retinopathy," Proteome Science, vol. 10, no. 1, article 15, 2012.
26. C. P. Wilkinson, F. L. Ferris III, R. E. Klein et al., "Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales," Ophthalmology, vol. 110, no. 9, pp. 1677-1682, 2003.
27. B. MacLean, D. M. Tomazela, N. Shulman et al., "Skyline: an open source document editor for creating and analyzing targeted proteomics experiments," Bioinformatics, vol. 26, no. 7, pp. 966-968, 2010.
28. K. Kim, S. J. Kim, H. G. Yu et al., "Verifcation of biomarkers for diabetic retinopathy by multiple reaction monitoring," Journal of Proteome Research, vol. 9, no. 2, pp. 689-699, 2010.
29. H. Keshishian, T. Addona, M. Burgess et al., "Quantifcation of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution," Molecular & Cellular Proteomics, vol. 8, no. 10, pp. 2339-2349, 2009.
30. B. Schilling, M. J. Rardin, B. X. MacLean et al., "Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation," Molecular & Cellular Proteomics, vol. 11, no. 5, pp. 202-214, 2012.
31. T. A. Addona, S. E. Abbatiello, B. Schilling et al., "Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma," Nature Biotechnology, vol. 27, no. 7, pp. 633-641, 2009.
32. W. R. Klecka, Discriminant Analysis, SAGE Publications, Beverly Hills, Calif, USA, 1980.
33. S.-W. Hyung, M. Y. Lee, J.-H. Yu et al., "A serum protein profle predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers," Molecular & Cellular Proteomics, vol. 10, no. 10, p. M111.011023, 2011.
34. T. A. Addona, X. Shi, H. Keshishian et al., "A pipeline that integrates the discovery and verifcation of plasma protein biomarkers reveals candidate markers for cardiovascular disease," Nature Biotechnology, vol. 29, no. 7, pp. 635-643, 2011.
35. D. Domanski, A. J. Percy, J. Yang et al., "MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma," Proteomics, vol. 12, no. 8, pp. 1222-1243, 2012.
36. G. L. Hortin, D. Sviridov, and N. L. Anderson, "High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance," Clinical Chemistry, vol. 54, no. 10, pp. 1608-1616, 2008.
37. N. E. Stathakis, A. Fountas, and E. Tsianos, "Plasma fbronectin in normal subjects and in various disease states," Journal of Clinical Pathology, vol. 34, no. 5, pp. 504-508, 1981.
38. A. Lutterotti, B. Kuenz, V. Gredler et al., "Increased serum levels of soluble CD14 indicate stable multiple sclerosis," Journal of Neuroimmunology, vol. 181, no. 1-2, pp. 145-149, 2006.
39. D. Domanski, G. V. C. Freue, L. Sojo et al., "Te use of multiplexed MRM for the discovery of biomarkers to diferentiate iron-defciency anemia from anemia of infammation," Journal of Proteomics, vol. 75, no. 12, pp. 3514-3528, 2012.
40. H. Loei, H. T. Tan, T. K. Lim et al., "Mining the gastric cancer secretome: identifcation of GRN as a potential diagnostic marker for early gastric cancer," Journal of Proteome Research, vol. 11, no. 3, pp. 1759-1772, 2012.
41. P. Kaur, N. M. Rizk, S. Ibrahim et al., "ITRAQ-based quantitative protein expression profling and MRM verifcation of markers in type 2 diabetes," Journal of Proteome Research, vol. 11, no. 11, pp. 5527-5539, 2012.
42. Y.-W. Kim, S. M. Bae, H. Lim, Y. J. Kim, and W. S. Ahn, "Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers," PLoS ONE, vol. 7, no. 9, Article ID e44960, 2012.